BR0309888A - Tratamento intracraniano de distúrbios neuropsiquiátricos por neurotoxinas clostridiais tal como a toxina da botulina - Google Patents

Tratamento intracraniano de distúrbios neuropsiquiátricos por neurotoxinas clostridiais tal como a toxina da botulina

Info

Publication number
BR0309888A
BR0309888A BR0309888-5A BR0309888A BR0309888A BR 0309888 A BR0309888 A BR 0309888A BR 0309888 A BR0309888 A BR 0309888A BR 0309888 A BR0309888 A BR 0309888A
Authority
BR
Brazil
Prior art keywords
botulinum toxin
neuropsychiatric disorders
clostridial neurotoxins
intracranial treatment
intracranial
Prior art date
Application number
BR0309888-5A
Other languages
English (en)
Inventor
Stephen Donovan
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of BR0309888A publication Critical patent/BR0309888A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

"TRATAMENTO INTRACRANIANO DE DISTúRBIOS NEUROPSIQUIáTRICOS POR NEUROTOXINAS CLOSTRIDIAIS TAL COMO A TOXINA DA BOTULINA". A presente invenção refere-se a processos para o tratamento de distúrbios neuropsiquiátricos que incluem a administração intracraniana de uma quantidade terapeuticamente eficaz de uma neurotoxina, tal como uma toxina botulínica do tipo A, a um paciente humano.
BR0309888-5A 2002-05-10 2003-04-11 Tratamento intracraniano de distúrbios neuropsiquiátricos por neurotoxinas clostridiais tal como a toxina da botulina BR0309888A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/143,078 US6921538B2 (en) 2002-05-10 2002-05-10 Therapeutic treatments for neuropsychiatric disorders
PCT/US2003/011416 WO2003094955A1 (en) 2002-05-10 2003-04-11 Intracranial treatment of neuropsychiatric disorders by clostridial neurotoxins such as botulinum toxin

Publications (1)

Publication Number Publication Date
BR0309888A true BR0309888A (pt) 2005-03-22

Family

ID=29400026

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0309888-5A BR0309888A (pt) 2002-05-10 2003-04-11 Tratamento intracraniano de distúrbios neuropsiquiátricos por neurotoxinas clostridiais tal como a toxina da botulina

Country Status (10)

Country Link
US (3) US6921538B2 (pt)
EP (1) EP1503790B1 (pt)
JP (1) JP4624777B2 (pt)
AT (1) ATE408416T1 (pt)
AU (1) AU2003221922B8 (pt)
BR (1) BR0309888A (pt)
CA (1) CA2484774C (pt)
DE (1) DE60323628D1 (pt)
ES (1) ES2314193T3 (pt)
WO (1) WO2003094955A1 (pt)

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7209787B2 (en) 1998-08-05 2007-04-24 Bioneuronics Corporation Apparatus and method for closed-loop intracranial stimulation for optimal control of neurological disease
US7747325B2 (en) 1998-08-05 2010-06-29 Neurovista Corporation Systems and methods for monitoring a patient's neurological disease state
US9113801B2 (en) 1998-08-05 2015-08-25 Cyberonics, Inc. Methods and systems for continuous EEG monitoring
US8762065B2 (en) 1998-08-05 2014-06-24 Cyberonics, Inc. Closed-loop feedback-driven neuromodulation
US9042988B2 (en) 1998-08-05 2015-05-26 Cyberonics, Inc. Closed-loop vagus nerve stimulation
US9375573B2 (en) 1998-08-05 2016-06-28 Cyberonics, Inc. Systems and methods for monitoring a patient's neurological disease state
US9415222B2 (en) 1998-08-05 2016-08-16 Cyberonics, Inc. Monitoring an epilepsy disease state with a supervisory module
EP1237476A1 (en) * 1999-12-02 2002-09-11 The General Hospital Corporation Method and apparatus for measuring indices of brain activity
US6306403B1 (en) * 2000-06-14 2001-10-23 Allergan Sales, Inc. Method for treating parkinson's disease with a botulinum toxin
US6921538B2 (en) * 2002-05-10 2005-07-26 Allergan, Inc. Therapeutic treatments for neuropsychiatric disorders
US7393537B2 (en) 2003-04-25 2008-07-01 Allergan, Inc. Botulinum toxin for treatment of obsessive compulsive finger biting disorder
US20040226556A1 (en) 2003-05-13 2004-11-18 Deem Mark E. Apparatus for treating asthma using neurotoxin
US8734810B2 (en) 2003-10-29 2014-05-27 Allergan, Inc. Botulinum toxin treatments of neurological and neuropsychiatric disorders
US8617572B2 (en) 2003-10-29 2013-12-31 Allergan, Inc. Botulinum toxin treatments of depression
US8609113B2 (en) 2003-10-29 2013-12-17 Allergan, Inc. Botulinum toxin treatments of depression
US8609112B2 (en) 2003-10-29 2013-12-17 Allergan, Inc. Botulinum toxin treatments of depression
US20050129677A1 (en) * 2003-12-10 2005-06-16 Shengwen Li Lipid rafts and clostridial toxins
US20100266638A1 (en) 2004-02-26 2010-10-21 Allergan, Inc. Headache treatment method
US7811584B2 (en) * 2004-06-30 2010-10-12 Allergan, Inc. Multivalent clostridial toxins
US7514088B2 (en) * 2005-03-15 2009-04-07 Allergan, Inc. Multivalent Clostridial toxin derivatives and methods of their use
AU2005279741B2 (en) 2004-09-01 2011-10-06 Allergan, Inc. Degradable clostridial toxins
US20060073208A1 (en) * 2004-10-01 2006-04-06 Allergan, Inc. Cosmetic neurotoxin compositions and methods
WO2006101809A1 (en) 2005-03-15 2006-09-28 Allergan, Inc. Modified clostridial toxins with enhanced targeting capabilities for endogenous clostridial toxin receptor systems
EP1920248B1 (en) 2005-04-05 2010-09-29 Allergan, Inc. Clostridial toxin activity assays
US20150258183A1 (en) 2006-06-07 2015-09-17 Botulinum Toxin Research Associates, Inc. Botulinum Toxin and the Treatment of Primary Disorders of Mood and Affect
CA2948238A1 (en) * 2005-06-14 2006-12-28 Revance Therapeutics, Inc. Botulinum toxin and the treatment of primary disorders of mood and affect
US8926991B2 (en) * 2005-06-14 2015-01-06 Botulinum Toxin Research Associates, Inc. Botulinum toxin and the treatment of primary disorders of mood and affect
US7655243B2 (en) 2005-07-22 2010-02-02 The Foundry, Llc Methods and systems for toxin delivery to the nasal cavity
US7608275B2 (en) 2005-07-22 2009-10-27 The Foundry, Llc Systems and methods for delivery of a therapeutic agent
US10052465B2 (en) 2005-07-22 2018-08-21 The Foundry, Llc Methods and systems for toxin delivery to the nasal cavity
US8725243B2 (en) 2005-12-28 2014-05-13 Cyberonics, Inc. Methods and systems for recommending an appropriate pharmacological treatment to a patient for managing epilepsy and other neurological disorders
US8868172B2 (en) 2005-12-28 2014-10-21 Cyberonics, Inc. Methods and systems for recommending an appropriate action to a patient for managing epilepsy and other neurological disorders
TWI417301B (zh) * 2006-02-21 2013-12-01 Wyeth Corp 對抗人類介白素-２２（ｉｌ-２２）之抗體及其用途
US7676263B2 (en) 2006-06-23 2010-03-09 Neurovista Corporation Minimally invasive system for selecting patient-specific therapy parameters
US8295934B2 (en) 2006-11-14 2012-10-23 Neurovista Corporation Systems and methods of reducing artifact in neurological stimulation systems
CA2673386A1 (en) * 2006-12-22 2008-07-03 Washington University High performance imaging system for diffuse optical tomography and associated method of use
WO2008092133A2 (en) 2007-01-25 2008-07-31 Neurovista Corporation Methods and systems for measuring a subject's susceptibility to a seizure
US9898656B2 (en) 2007-01-25 2018-02-20 Cyberonics, Inc. Systems and methods for identifying a contra-ictal condition in a subject
US8036736B2 (en) 2007-03-21 2011-10-11 Neuro Vista Corporation Implantable systems and methods for identifying a contra-ictal condition in a subject
US9788744B2 (en) 2007-07-27 2017-10-17 Cyberonics, Inc. Systems for monitoring brain activity and patient advisory device
US20090171168A1 (en) 2007-12-28 2009-07-02 Leyde Kent W Systems and Method for Recording Clinical Manifestations of a Seizure
US9259591B2 (en) 2007-12-28 2016-02-16 Cyberonics, Inc. Housing for an implantable medical device
US8483831B1 (en) 2008-02-15 2013-07-09 Holaira, Inc. System and method for bronchial dilation
US9480425B2 (en) * 2008-04-17 2016-11-01 Washington University Task-less optical mapping of dynamic brain function using resting state functional connectivity
AU2009244058B2 (en) 2008-05-09 2015-07-02 Nuvaira, Inc Systems, assemblies, and methods for treating a bronchial tree
JPWO2010013495A1 (ja) * 2008-07-31 2012-01-05 一般財団法人化学及血清療法研究所 高度精製ボツリヌス毒素治療剤を有効成分として含有する薬学的組成物およびその利用
US8849390B2 (en) 2008-12-29 2014-09-30 Cyberonics, Inc. Processing for multi-channel signals
US8588933B2 (en) 2009-01-09 2013-11-19 Cyberonics, Inc. Medical lead termination sleeve for implantable medical devices
US8786624B2 (en) 2009-06-02 2014-07-22 Cyberonics, Inc. Processing for multi-channel signals
WO2011041483A2 (en) 2009-09-30 2011-04-07 Toxcure, Inc. Use of botulinum neurotoxin to treat substance addictions
WO2011056684A2 (en) 2009-10-27 2011-05-12 Innovative Pulmonary Solutions, Inc. Delivery devices with coolable energy emitting assemblies
US9149328B2 (en) 2009-11-11 2015-10-06 Holaira, Inc. Systems, apparatuses, and methods for treating tissue and controlling stenosis
US8911439B2 (en) 2009-11-11 2014-12-16 Holaira, Inc. Non-invasive and minimally invasive denervation methods and systems for performing the same
JP2011157331A (ja) * 2010-02-03 2011-08-18 Chemo-Sero-Therapeutic Research Inst 高用量投与が可能なボツリヌス毒素製剤
US9643019B2 (en) 2010-02-12 2017-05-09 Cyberonics, Inc. Neurological monitoring and alerts
US8940308B2 (en) 2010-03-30 2015-01-27 Allergan, Inc. Methods for treating depression
WO2012174123A1 (en) 2011-06-13 2012-12-20 Allergan, Inc. Treatment of psychological trauma
EP2649985A1 (en) 2012-04-13 2013-10-16 Lipotec, S.A. Compounds which inhibit neuronal exocytosis (III)
EP2649983A1 (en) 2012-04-13 2013-10-16 Lipotec, S.A. Compounds which inhibit neuronal exocytosis (II)
EP2649984A1 (en) 2012-04-13 2013-10-16 Lipotec, S.A. Compounds which inhibit neuronal exocytosis
MX356343B (es) 2012-04-13 2018-05-23 Lubrizol Advanced Mat Inc Compuestos que inhiben la exocitosis neuronal (ii).
US9005628B2 (en) 2012-10-04 2015-04-14 Dublin City University Biotherapy for pain
WO2014078724A1 (en) * 2012-11-16 2014-05-22 Finzi Eric Treatment of post-traumatic stress disorder using botulinum toxin a
US9398933B2 (en) 2012-12-27 2016-07-26 Holaira, Inc. Methods for improving drug efficacy including a combination of drug administration and nerve modulation
GB201312317D0 (en) 2013-07-09 2013-08-21 Syntaxin Ltd Cationic neurotoxins
GB201313356D0 (en) * 2013-07-26 2013-09-11 Ucl Business Plc Therapeutic Intervention
US9216210B2 (en) 2013-12-23 2015-12-22 Dublin City University Multiprotease therapeutics for chronic pain
US9950194B2 (en) 2014-09-09 2018-04-24 Mevion Medical Systems, Inc. Patient positioning system
WO2016110662A1 (en) 2015-01-09 2016-07-14 Ipsen Bioinnovation Limited Cationic neurotoxins
WO2016149092A1 (en) 2015-03-13 2016-09-22 Allergan, Inc. Improved injection paradigm for administration of botulinum toxins
GB201517450D0 (en) 2015-10-02 2015-11-18 Ipsen Biopharm Ltd Method
GB201607901D0 (en) 2016-05-05 2016-06-22 Ipsen Biopharm Ltd Chimeric neurotoxins
EP3263710A1 (en) 2016-07-01 2018-01-03 Ipsen Biopharm Limited Production of activated clostridial neurotoxins
JP7118055B2 (ja) 2016-09-29 2022-08-15 イプセン バイオファーム リミテッド ハイブリッド神経毒
US10786010B2 (en) 2017-12-15 2020-09-29 Rai Strategic Holdings, Inc. Aerosol delivery device with multiple aerosol delivery pathways
US20210187194A1 (en) 2018-02-26 2021-06-24 Ipsen Biopharm Limited Use of Ultrasound to Guide Injection of Non-cytotoxic Protease
US20220002438A1 (en) 2018-09-10 2022-01-06 ACADEMISCH ZIEKENHUIS LEIDEN (h.o.d.n. LUMC) Musk inhibition
KR102520625B1 (ko) 2019-10-18 2023-04-12 펜랜드 파운데이션 치료에 사용하기 위한 보톨리늄 독소
GB201917265D0 (en) 2019-11-27 2020-01-08 Univ Sheffield Bonded neurotoxins
GEP20247609B (en) 2019-12-20 2024-03-11 Ipsen Biopharm Ltd Ethod of producing botulinum toxin
WO2021212053A2 (en) 2020-04-17 2021-10-21 Newyork University Therapeutic musk antibodies
CN113832069B (zh) * 2020-11-30 2024-01-30 河南农业大学 丁酸梭菌及其应用
GB202103372D0 (en) 2021-03-11 2021-04-28 Ipsen Biopharm Ltd Modified clostridial neurotoxins
WO2024069191A1 (en) 2022-09-30 2024-04-04 Ipsen Biopharm Limited Clostridial neurotoxin for use in a treatment of bladder pain syndrome

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4741902A (en) * 1986-07-14 1988-05-03 Haast William E Compositions for treatment of neurological and related disorders
US5352447A (en) * 1987-10-05 1994-10-04 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Immunotoxins for treatment of intracranial lesions and as adjunct to chemotherapy
DE4004573A1 (de) * 1989-02-17 1990-08-23 Tanabe Seiyaku Co Neues versuchstier und seine herstellung
US5549884A (en) * 1992-10-28 1996-08-27 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Rat or mouse exhibiting behaviors associated with human schizophrenia
US5562907A (en) * 1993-05-14 1996-10-08 Arnon; Stephen S. Method to prevent side-effects and insensitivity to the therapeutic uses of toxins
US5545617A (en) * 1993-11-12 1996-08-13 The Schepens Eye Research Institute, Inc. Therapeutic regulation of abnormal conjunctival goblet cell mucous secretion
US6974578B1 (en) * 1993-12-28 2005-12-13 Allergan, Inc. Method for treating secretions and glands using botulinum toxin
EP1147776B1 (en) * 1993-12-28 2010-12-15 Allergan, Inc. Use of botulinum toxin type B for the manufacture of a medicament for the treatment of muscle spasms
US5766605A (en) * 1994-04-15 1998-06-16 Mount Sinai School Of Medicine Of The City University Of New York Treatment of autonomic nerve dysfunction with botulinum toxin
ES2238969T3 (es) * 1994-05-09 2005-09-16 William J. Binder Neurotoxinas presinapticas para el tratamiento de cefaleas migrañosas.
ES2138740T3 (es) * 1994-05-31 2000-01-16 Allergan Inc Modificacion de toxinas de clostridium utilizadas como proteinas de transporte.
SE9401965D0 (sv) * 1994-06-07 1994-06-07 Astra Ab New compounds
GB9508204D0 (en) 1995-04-21 1995-06-07 Speywood Lab Ltd A novel agent able to modify peripheral afferent function
US6071493A (en) * 1996-09-20 2000-06-06 Baylor College Of Medicine Method of screening for an agent that inhibits mononuclear phagocyte-plaque component complex formation
US6272370B1 (en) * 1998-08-07 2001-08-07 The Regents Of University Of Minnesota MR-visible medical device for neurological interventions using nonlinear magnetic stereotaxis and a method imaging
AU3748499A (en) * 1998-04-29 1999-11-16 Allergan, Inc. Compositions and methods for extending the action of clostridial neurotoxin
CN1318105A (zh) * 1998-09-15 2001-10-17 M&E生物技术公司 负调节Osteoprotegerin配体活性的方法
KR20010089347A (ko) * 1998-10-27 2001-10-06 메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치 상처 치료 증진 방법
US6545126B1 (en) * 1999-03-18 2003-04-08 Wisconsin Alumni Research Foundation Chimeric toxins
US6113915A (en) * 1999-10-12 2000-09-05 Allergan Sales, Inc. Methods for treating pain
US6429189B1 (en) * 1999-12-10 2002-08-06 Botulinum Toxin Research Associates, Inc. Cytotoxin (non-neurotoxin) for the treatment of human headache disorders and inflammatory diseases
US6524580B1 (en) * 2000-02-15 2003-02-25 Allergan Sales, Inc. Method for treating thyroid disorders
US20010036943A1 (en) * 2000-04-07 2001-11-01 Coe Jotham W. Pharmaceutical composition for treatment of acute, chronic pain and/or neuropathic pain and migraines
US6464986B1 (en) * 2000-04-14 2002-10-15 Allegan Sales, Inc. Method for treating pain by peripheral administration of a neurotoxin
US6306423B1 (en) * 2000-06-02 2001-10-23 Allergan Sales, Inc. Neurotoxin implant
US6306403B1 (en) * 2000-06-14 2001-10-23 Allergan Sales, Inc. Method for treating parkinson's disease with a botulinum toxin
US6827931B1 (en) * 2000-10-20 2004-12-07 Allergan, Inc. Method for treating endocrine disorders
US6787517B1 (en) * 2000-12-29 2004-09-07 Allergan, Inc. Agent and methods for treating pain
US20020192239A1 (en) * 2001-01-09 2002-12-19 Borodic Gary E. Use of botulinum toxin for the treatment of chronic facial pain
WO2003015698A2 (en) * 2001-08-13 2003-02-27 University Of Pittsburgh Application of lipid vehicles and use for drug delivery
US7255866B2 (en) * 2001-09-17 2007-08-14 Allergan, Inc. Botulinum toxin therapy for fibromyalgia
US6623742B2 (en) * 2001-09-17 2003-09-23 Allergan, Inc. Methods for treating fibromyalgia
DE10150415A1 (de) 2001-10-11 2003-05-15 Andres O Ceballos-Baumann Arzneimittel zur Prophylaxe und Therapie von Depressionen
US6921538B2 (en) * 2002-05-10 2005-07-26 Allergan, Inc. Therapeutic treatments for neuropsychiatric disorders
US7390496B2 (en) * 2003-04-25 2008-06-24 Allergan, Inc. Therapeutic treatments for repetitive hand washing
US8734810B2 (en) * 2003-10-29 2014-05-27 Allergan, Inc. Botulinum toxin treatments of neurological and neuropsychiatric disorders
US7270287B2 (en) * 2004-01-06 2007-09-18 Allergan, Inc. Botulinum toxin treatment for kinesia
US7897147B2 (en) * 2004-10-20 2011-03-01 Allergan, Inc. Treatment of premenstrual disorders

Also Published As

Publication number Publication date
US20070218085A1 (en) 2007-09-20
US7229626B2 (en) 2007-06-12
US6921538B2 (en) 2005-07-26
AU2003221922B2 (en) 2006-09-28
JP4624777B2 (ja) 2011-02-02
US20040180061A1 (en) 2004-09-16
EP1503790A1 (en) 2005-02-09
CA2484774A1 (en) 2003-11-20
AU2003221922A1 (en) 2003-11-11
WO2003094955A1 (en) 2003-11-20
EP1503790B1 (en) 2008-09-17
ES2314193T3 (es) 2009-03-16
US7811587B2 (en) 2010-10-12
CA2484774C (en) 2012-07-10
DE60323628D1 (de) 2008-10-30
ATE408416T1 (de) 2008-10-15
JP2005530770A (ja) 2005-10-13
AU2003221922B8 (en) 2009-06-18
US20030211121A1 (en) 2003-11-13

Similar Documents

Publication Publication Date Title
BR0309888A (pt) Tratamento intracraniano de distúrbios neuropsiquiátricos por neurotoxinas clostridiais tal como a toxina da botulina
BR0111698A (pt) Método para o tratamento de um distúrbio de movimento
MXPA02009932A (es) Metodo apra el tratamiento del dolor mediante administracion periferica de una neurotoxina.
BR0014710A (pt) Métodos para o tratamento de dor
BRPI0417493A (pt) terapia com toxina botulìnica para distúrbios da pele
BRPI0910993A2 (pt) técnica de administração na linha de sutura usando toxinas botulínicas
MXPA03002576A (es) Metodos para tratar lesiones musculares.
AR028939A1 (es) Metodo para tratar un desorden pancreatico con una neurotoxina
BR0307496A (pt) Uso de uma neurotoxina clostridiana, bem como composição farmacêutica utilizável no tratamento de um distúrbio da glândula mamária
BRPI0415558A (pt) tratamentos com toxina de botulina de distúrbios neurológicos e neuropsiquiátricos
HRP20050903A2 (en) Intravenous injection of plasminogen non-neurotoxic activators for treating cerebral stroke
LU92052I2 (fr) Toxine botulique de Clostridium botulinum
BR0315158A (pt) Compostos de pirazol para o tratamento de distúrbios neurodegenarativos
CY1114792T1 (el) Κλωστριδιακες τοξινες για χρηση στην θεραπεια προωρης εκσπερματισης
ATE373679T1 (de) Antimikrobiell wirksames oder endotoxin neutralisierendes polypeptid
ATE462443T1 (de) Dehnungsstreifenbehandlung mit botulinumtoxin
MX2022010186A (es) Neurotoxinas botulinas para uso en terapia.
BRPI0509477A (pt) compostos de sulfonamida para o tratamento de distúrbios neurodegenerativos
MX2024006763A (es) Tratamiento de enfermedades neurológicas utilizando moduladores de los transcritos del gen unc13a.
EA200601238A1 (ru) Медикаменты для профилактики и лечения бромидроза и для улучшения запаха тела
BRPI0509478A (pt) tratamento de ferida por pressão
MY151447A (en) Intravenous injection of non-neurotoxic plasminogen activators for the treatment of stroke
BRPI0514895A (pt) tratamento de estria

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B11E Dismissal acc. art. 34 of ipl - requirements for examination incomplete
B11T Dismissal of application maintained [chapter 11.20 patent gazette]